NASDAQ · Medical - Devices

LUNG (LUNG) Stock

$1.22 +4.27% NASDAQ: LUNG Healthcare

Valuation

MetricValue
Price$1.22
Market Cap$51.53M
P/E Ratio-1.23
P/B Ratio1.18
P/S Ratio0.61
EPS (TTM)$-1.05
52-Week High$3.88
52-Week Low$1.13
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-86.22%
ROA-24.04%
ROCE-100.00%
Gross Margin75.49%
Operating Margin-58.79%
Net Margin-60.09%
Debt/Equity1.23
Current Ratio5.10

Annual Financials (USD)

Metric20212022202320242025
Revenue$48.0M$54.0M$69.0M$84.0M$90.0M
Operating Profit$-47.0M$-59.0M$-62.0M$-58.0M$-54.0M
Net Profit$-49.0M$-59.0M$-61.0M$-56.0M$-54.0M
EPS$-1.35$-1.59$-1.60$-1.44$-1.33
Op Margin-97.7%-109.3%-90.2%-68.9%-59.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$235.0M$194.0M$178.0M$163.0M$129.0M
Total Liabilities$42.0M$40.0M$59.0M$77.0M$75.0M
Cash$148.0M$102.0M$84.0M$71.0M$70.0M
Borrowings$26.0M$24.0M$41.0M$56.0M$56.0M

Latest News

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026 GlobeNewswire · Jul 15, 2026 Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 1, 2026 Pulmonx (LUNG) Q1 2026 Earnings Transcript Motley Fool · Apr 30, 2026 Pulmonx Corporation Q1 2026 Earnings Call Summary Moby · Apr 30, 2026 Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... GuruFocus.com · Apr 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-41.0M$-45.0M$-38.0M$-32.0M$-32.0M
Investing Cash Flow$-50.0M$-6.0M$-3.0M$16.0M$30.0M
Financing Cash Flow$0$0$1.0M$1.0M$0
Net Cash Flow$-83.0M$-47.0M$-18.0M$-13.0M$-1.0M
Free Cash Flow$-45.0M$-46.0M$-38.0M$-33.0M$-33.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-28.92
EV / EBITDA-0.95
FCF Yield-54.49%
Quick Ratio4.04
Interest Coverage-18.00
Return 1Y-46.30%
Return 3Y-89.24%
Return 5Y-96.16%

Ownership

Insiders Held4.89%
Institutions Held78.83%
Institutions Float Held82.88%
Institutional HolderSharesReport Date
Primecap Management Company4,724,9912026-03-31
Morgan Stanley3,993,5622026-03-31
Soleus Capital Management, L.P.2,788,3232026-03-31
Blackrock Inc.2,661,6072026-03-31
ExodusPoint Capital Management, LP1,943,8342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRV $1.73 +2.37% -0.95 $74.05M 0.00%
ASRT $23.44 +0.30% -4.95 $151.47M 0.00%
EDAPEdap Tms S.a. $4.76 -0.52% -6.63 $178.23M 0.00%
HYPR $0.94 +0.99% -3.44 $78.94M 0.00%
IMUXImmunic, Inc. $13.81 +3.14% -2.24 $188.11M 0.00%

About LUNG

LUNG is led by CEO Glendon E. French, employs 291 people, headquartered in US, publicly traded since 2020.

LUNG stock trades at $1.22 with a market capitalization of $51.53M. The stock is valued at a price-to-earnings (P/E) ratio of -1.23, price-to-book of 1.18, price-to-sales of 0.61. Over the past 52 weeks the stock has ranged between $1.13 and $3.88, and currently trades 68.6% below its 52-week high.

On profitability, LUNG generates a return on equity (ROE) of -86.22%, return on capital employed of -100.00%, an operating margin of -58.79%, a net profit margin of -60.09%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides